



LGE-MRI Characterization of Left Atrial Fibrosis: a Tool to Establish Prognosis and Guide Atrial Fibrillation Ablation

Eva M. Benito^{1,2,3} · Francisco Alarcon^{1,2,3} · Lluís Mont^{1,2,3,4}

Published online: 28 March 2019
© Springer Science+Business Media, LLC, part of Springer Nature 2019

Abstract

Purpose of Review Atrial fibrillation (AF) is the most frequent arrhythmia and also an important cause of morbidity, hospitalization, and mortality. Pulmonary vein isolation (PVI) is often the preferred therapy, but the incidence of recurrences is still significant. This review summarizes the contribution of atrial substrate identification using late gadolinium enhancement magnetic resonance imaging (LGE-MRI) to establish prognosis and to guide AF ablation.

Recent Findings Left atrial (LA) fibrosis is thought to create the necessary substrate to sustain AF. The accuracy of LGE-MRI to identify areas of atrial fibrosis remains controversial. However, the amount of LA fibrosis visible in the 3D reconstruction of LGE-MRI has been identified as a sign for AF progression and poor outcome after ablation. Additionally, the scar created by radiofrequency and cryoablation lesions can be visualized after the procedures. Discontinuities in PVI ablation lines have been related to recurrence and can be used to identify electrical reconnections. Ongoing research is directed toward validating fibrosis ablation as a new target to improve ablation outcomes.

Summary Atrial fibrosis assessment by LGE-MRI may show the severity of atrial disease and could be used to select patients likely to benefit the most from AF ablation. Usefulness of an individually tailored LGE-MRI-guided ablation approach is still under evaluation.

Keywords Atrial fibrosis · Atrial fibrillation · Catheter ablation · Late gadolinium enhancement magnetic resonance · Substrate

Abbreviations

AF	Atrial fibrillation
IIR	Image intensity ratio
LGE-MRI	Late gadolinium enhancement magnetic resonance

LA	Left atrium
PVI	Pulmonary vein isolation
SI	Signal intensity

This article is part of the Topical Collection on *Arrhythmias*

✉ Lluís Mont
lmont@clinic.cat

Eva M. Benito
Benitom@clinic.cat

Francisco Alarcon
Falarcon@clinic.cat

- ¹ Institut Clínic Cardiovascular, Hospital Clinic, Universitat de Barcelona, Barcelona, Catalonia, Spain
- ² Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Catalonia, Spain
- ³ Cardiology Department, Hospital Clinic, C/Villarroel, 170, 08036 Barcelona, Spain
- ⁴ CIBERCV, Instituto de Salud Carlos III, Madrid, Spain

Introduction

Characterization of left atrial (LA) fibrosis using late gadolinium enhancement magnetic resonance imaging (LGE-MRI) has emerged as a promising technique to identify and quantify fibrotic tissue [1, 2, 3]. The amount and location of atrial fibrosis may have clinical implications in prognosis and treatment of atrial fibrillation (AF) [4, 5, 6]. This review aims to summarize the currently available trials focused on atrial substrate identification by LGE-MRI directed to establish prognosis and to guide atrial fibrillation procedures.

Left Atrial Remodeling: Atrial Fibrosis

Structural remodeling of the left atrium can be evidenced by collagen deposition in the interstitial space of myocardial fibers.

The presence and degree of fibrotic tissue are related to the etiology and progression of atrial fibrillation [7, 8]. Atrial fibrosis increases with age and is more frequent in patients with cardiomyopathies or hypertension [9], but also has been reported in patients with AF but no structural heart disease (*lone AF*) [4].

LGE-MRI: a Non-Invasive Tool for the Assessment of Atrial Fibrosis

LGE-MRI detects myocardial fibrosis. The paramagnetic metal present in gadolinium-based contrast agents has the ability to accumulate in the extracellular space, modifying the magnetic properties of water. As fibrotic tissue has a greater proportion of extracellular space, compared to healthy myocardium [10], gadolinium accumulates in this expanded extracellular space after infusion of contrast. The resulting delay in the contrast wash in and wash out leads to higher signal intensity (SI) in T1-weighted MRI scans [11].

Although fibrosis visualization in LGE-MRI has been widely adopted at the ventricular myocardium level [12], the limited spatial resolution of MRI scanning results in a challenge for accuracy in fibrosis discrimination in the narrower atrium walls. Several acquisition protocols and post-processing software approaches are being used, mainly as a research tool [13•]; their use in clinical practice remains limited. Table 1 summarizes the different approaches reported to

date in native atrium [1, 2•, 3•, 6••, 26] and in post-ablation patients [17••, 20••, 22, 28, 29].

Image Post-Processing Algorithms and Thresholds to Identify Atrial Fibrosis

Acquisition image protocols, either in 1.5 T or 3 T MRI scanners, are similar between groups. The main differences are related to the algorithms used for post-processing and the method for choosing the SI threshold to define fibrosis. The Utah group uses the Corview image processing and analysis software (Marrek, Salt Lake City, Utah) with a dynamic threshold based on a histological validation [5]. This method was also used in the largest prospective multicenter study of outcomes in atrial fibrillation ablation to date [6••]. We consider that the main limitation of this approach is the need for an expert eye to define thresholds, making external validation and reproducibility difficult.

Khurram et al. normalized SI with blood pool intensity (image intensity ratio (IIR)) [2•], establishing a threshold validated by low-voltage areas, considered as a voltage below 0.5 mV. Our group established a fixed threshold of 1.20 mV, based on two standard deviations from SI in young healthy subjects. More recently, Khurram et al. adjusted their threshold to 0.3 mV and reported better correlation with histology specimens having chronic scar [21•]; the IIR threshold obtained was similar to that later reported by our group [15, 30].

Table 1 Differences between centers in LGE-MRI acquisition and post-processed protocols for fibrosis assessment

Methodology by center	Scan magnet strength	Voxel size	IT (ms)	Scan time (min)	Fibrosis visualization methodology	Threshold
CARMA/DECAAF centers. Salt Lake City, Utah [1, 4, 6••, 14]	1.25 × 1.25 × 2.5	1.5 T/3 T	nr	15	SD above ref. histogram	Mean SI of normal tissue + 2/4 SD
J. Hopkins Baltimore [2•, 15, 16••]	1.3 × 1.3 × 2.0	1.5 T	240–290	15–25	IIR	Voltage validation set at 0.5–0.1 V; IIR: 0.97–1.6
Clinic H Barcelona ([3•, 17••, 18•, 19••])	1.25 × 1.25 × 2.5	3 T	280–380	11–18	Maximum scar density %/IIR	40–60% MPI Mean IIR + 2 SD healthy population (1.20)
King's College London [20••, 21•]	1.3 × 1.3 × 4.0	1.5 T	nr	20	SD above ref. blood pool	Mean SI blood pool + 2.3 to 3.3 SD (acute and chronic post-ablation)
Beth Israel Boston [22, 23]	1.3 × 1.3 × 4.0	1.5 T	280	15–25	Visual assessment	Expert characterization
CHU Bourdeaux [24]	1.25 × 1.25 × 2.5	1.5 T	260–320	5–10	SD above ref. histogram	Mean SI of normal tissue 2/4 SD
Imperial College London [25]	1.5 × 1.5 × 4.0	1.5 T	nr	12–20	SD above ref. blood pool	Voltage validation set at 3 SD above blood pool
Prague [26]	1.6 × 1.6	1.5 T	270	11 4	SD above ref. histogram FWHM	Mean SI of nulled myocardium + 6 SD SI mitral valve-SI min/2
Korea [27]	1.5 × 1.5	3 T	230–270	15–25	SD above nulled myocardium FWHM	Mean SI of normal tissue + 3–5 SD Th SI max-SI min/2

IIR, image intensity ratio; MPI, maximum pixel intensity; ms, milliseconds; min, minutes; nr, not reported; SD, standard deviations; SI, signal intensity

Karim et al. [31] provide the only study that compares some of these algorithms of post-processed LGE-MRI obtained in the same population with AF. They found wide discrepancies but observed the best correlation in patients with a previous ablation procedure. Induced dense scarring is more visible and better discriminates between scar and non-scar tissue. Detection of native fibrosis will continue to be challenging, as atrial collagen deposition is a continuous variable with an unknown degree of overlap between healthy individuals and patients with AF. The desire to establish a threshold and transform

it into a qualitative variable is understandable, but this certainly represents an oversimplification of actual histological changes.

LGE-MRI in the Prediction of Outcomes After Atrial Fibrillation Ablation

Catheter ablation is the therapy of choice in symptomatic AF patients' refractory to antiarrhythmic drugs [32]. However, the post-ablation success rate is still limited, particularly in persistent AF [33]. Better protocols for selection of ablation

Table 2 Available trials about the usefulness of atrial fibrosis identified in LGE-MRI in atrial fibrillation ablation procedures

Study	Year	Study type	N	MRI performed	Results
LGE-MRI: atrial fibrosis as a predictor of outcomes in atrial fibrillation ablation					
Peters et al. [23]	2009	Observational Single center	35	Post-ablation	Lesser atrial scarring after PVI is associated with recurrence
Akoum et al. [14]	2011	Observational Single center	144	Pre-ablation Post-ablation	In mild/moderate UTAH stages, post-ablation scarring predicts recurrences
Malcolme-Lawes et al. [25]	2013	Observational Bi-center	50	Pre-ablation	Greater pre-ablation percentage of LA scar is associated with recurrences
Marrouche et al. (DECAAF trial) [6••]	2014	Observational Multicenter	329	Pre-ablation	Atrial fibrosis is independently associated with recurrence
Mcgann et al. [5]	2014	Observational Single center	426	Pre-ablation	Extensive atrial fibrosis (> 30% LA) is a predictor of poor response to catheter ablation
Sramko et al. [26]	2015	Observational Single center	95	Pre-ablation	Extent of LGE does not predict recurrences.
Akoum et al. [38•]	2015	Observational Multicenter	172	Pre-ablation Post-ablation	Baseline and residual fibrosis are predictors of recurrences A number of pulmonary veins completely encircled is not related to outcomes.
Khurram et al. [16••]	2016	Observational Single center	165	Pre-ablation	Advanced stages of fibrosis (LGE > 35%) are associated with poor outcomes.
Den Uijl et al. [18•]	2018	Observational Single center	83	Pre-ablation	No significant relationship between absolute fibrosis degree and recurrence UTAH stage IV tended to show a higher risk of recurrence.
Linhart et al. [19••]	2018	Observational Single center	94	Post-ablation	Total relative gap length is associated with AF recurrence.
Guided substrate ablation assessed by MRI					
Bisbal et al. [17••]	2014	Experimental (non-randomized) Single center	15	Post-ablation (Redo-procedures)	LGE-MRI is useful to guide redo-procedures, reducing procedural and RF time.
Harrison et al. [20••]	2015	Observational Single center	22	Post-ablation (Redo-procedures)	LGE-MRI is unable to predict sites of electrical reconnections.
Utah, DECAAF II [39••]	Recruiting	Experimental Randomized Multicenter	888 (expected)	Pre-ablation	NR
Barcelona ALICIA [40]	Recruiting	Experimental Randomized Bi-center	154 (expected)	Pre-ablation Post-ablation	NR

AF, atrial fibrillation; LA, left atrium; LGE-MRI, late gadolinium enhancement magnetic resonance; NR, no results; PVI, pulmonary vein isolation

candidates may avoid risks and multiple unsuccessful interventions in patients with little chance of response.

Advanced atrial disease is related to poor outcomes after ablation [34]. Several parameters have been used to identify the severity of atrial remodeling, and LA diameter [35], LA volume [18•], atrial fibrosis [34], and sphericity [36, 37] have been described as predictors of success. On the other hand, a number of studies have tested the accuracy of LGE-MRI detection of atrial fibrosis in predicting outcomes after AF ablation, with conflicting results (Table 2).

The Utah group proposed a classification based in LGE percentage in LA as a powerful independent predictor of outcomes [5, 6••, 38•]. Reported recurrences increased progressively with the severity of fibrosis, and ablation had a very low success rate in advanced stages of fibrosis (classified as UTAH-IV). In the multicenter DECAAF study, probabilities of recurrence increased up to 6% per 1% increase in global atrial fibrosis [6••]. Khurram et al. reported similar results, with a 1.5-fold increased hazard of AF recurrence for each 10% increment in LGE. More than a 35% LGE extension predicted less than 50% success at 1-year follow-up [16••]. However, other studies have not found LA fibrosis assessment to have predictive value [18•, 26]. Using the same methodology as Khurram et al. but a more restrictive threshold for fibrosis, Den Uijl et al. found a higher recurrence rate in patients classified as stage UTAH-IV, compared to I-III UTAH stages [18•].

LGE-MRI is also useful to detect lesions induced by catheter ablation [14, 21•, 22] and may localize the potential discontinuities in ablation lines [17••, 19••]. Peters et al. reported that the total amount of post-ablation scar was related to recurrences [23]. Although Akoum et al. confirmed those results; they found no predictive value for patients with advanced stages of fibrosis pre-ablation [14]. In an earlier study, researchers found that, in most cases, recurrences are related to PVI reconnections [41]. According to Linhart et al., recurrences are not related to the number of discontinuities or complete PVIs, but are powerfully related to the total relative gap length; for each 10% of the increase in relative length, recurrences increased 16% [19••].

Substrate Atrial Fibrosis as a New Target for Ablation Procedures

Improving the results of AF ablation remains challenging. Although PVI is well established as the standard procedure for treating paroxysmal AF [42], its success rate in non-paroxysmal AF is modest despite additional linear ablation or the elimination of complex fractionated atrial electrograms [43, 44]. Targeting the fibrotic atrial substrate is reportedly useful, but has not been validated in large randomized trials [45]. Furthermore, the AF phenotype is not always correlated with the degree of remodeling [46].

Appropriate selection of patients who could benefit from an extensive LA substrate-based ablation approach could be the key to obtain better results. Atrial substrate modification based on voltage criteria has recently been evaluated with promising results [47–49]. Use of LA characterization by LGE-MRI to define areas with significant native fibrosis as an ablation target is being tested in a small randomized trial (ALICIA) [40] and in a multicenter trial (DECAAF II) [39••]. In patients undergoing a first ablation procedure, the fibrotic areas identified by LGE-MRI are isolated or ablated. The ALICIA study is also evaluating the utility of LGE-MRI to guide re-ablation procedures [40], as illustrated in Fig. 1. Bisbal et al. reported redo-ablation guided only by LGE-MRI and blinded to electrical voltage reconnections. Although concordance between the electrical site of reconnections and cardiac MRI was observed in 79% of cases, the ablation of LGE-MRI gaps achieved isolation in 95.6% of veins [17••]. Harrison et al. reported that LGE-MRI was not sufficiently accurate to detect gaps when voltage comparison was performed, although the lack of a blinded design was a limitation of the study [20••].

Finally, evaluation of electrical gaps by circular catheter may have pitfalls that could explain discrepancies between LGE-MRI and electrical mapping [50]. New multipolar electrodes have the potential to better identify the location of functional gaps and show improved correlation with LGE-MRI [51].




Fig. 1 Individually tailored ablation guided by LGE-MRI. Panel **a** shows conventional first ablation procedure: PVI in a patient with minimal fibrosis around the veins. Panel **b** shows individually tailored reablation of anatomical “gaps” guided by LGE-MRI. Panel **c** shows

individually tailored first ablation procedure guided by LGE-MRI: PVI + isolation of areas with significant fibrosis. (PVI, pulmonary vein isolation; LGE-MRI, late gadolinium enhancement magnetic resonance)

Conclusions

Use of LGE-MRI has been shown to accurately detect, quantify, and characterize atrial fibrosis, and also to predict patient outcomes after AF ablation. Although this makes it a promising tool for appropriate patient selection, its use in clinical practice remains limited by the lack of standardized acquisition protocols and SI thresholds. Furthermore, the potential benefit of substrate-guided ablation is still being evaluated. As research continues, future improvements in image technology, software, and clinical guidelines may help to translate the acquired knowledge to daily clinical practice.

Compliance with Ethical Standards

Conflict of Interest L Mont is a shareholder of Galgo Medical Company. The other authors declare that they have no conflicts.

Human and Animal Rights and Informed Consent This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as:

- Of importance
- Of major importance

1. Oakes RS, Badger TJ, Kholmovski EG, Akoum N, Burgon NS, Fish EN, et al. Detection and quantification of left atrial structural remodeling with delayed-enhancement magnetic resonance imaging in patients with atrial fibrillation. *Circulation*. 2009;119(13):1758–67. <https://doi.org/10.1161/CIRCULATIONAHA.108.811877>.
- 2.• Khurram IM, Beinart R, Zipunnikov V, Dewire J, Yarmohammadi H, Sasaki T, et al. Magnetic resonance image intensity ratio, a normalized measure to enable interpatient comparability of left atrial fibrosis. *Heart Rhythm*. 2014;11(1):85–92. <https://doi.org/10.1016/j.hrthm.2013.10.007> **This study reported a method to quantify LA fibrosis, based in a normalized measure: image intensity ratio(IIR) defined as LA myocardial signal intensity divided by the mean LA blood pool signal intensity. IIR showed good correlation with intracardiac voltage.**
- 3.• Benito EM, Carlosena-Remirez A, Guasch E, Prat-Gonzalez S, Perea RJ, Figueras R, et al. Left atrial fibrosis quantification by late gadolinium-enhanced magnetic resonance: a new method to standardize the thresholds for reproducibility. *Europace*. 2017;19(8):1272–9. <https://doi.org/10.1093/europace/euw219> **This study aimed to obtain a comparable threshold between individuals of image intensity ratio (IIR) in order to detect LA fibrosis, based in a control group of young healthy volunteers. An IIR > 1.20 identified abnormal fibrotic tissue. IIR >1.32 was observed in dense scars of post-ablation patients.**
4. Mahnkopf C, Badger TJ, Burgon NS, Daccarett M, Haslam TS, Badger CT, et al. Evaluation of the left atrial substrate in patients with lone atrial fibrillation using delayed-enhanced MRI: implications for disease progression and response to catheter ablation. *Heart Rhythm*. 2010;7(10):1475–81. <https://doi.org/10.1016/j.hrthm.2010.06.030>.
5. McGann C, Akoum N, Patel A, Kholmovski E, Revelo P, Damal K, et al. Atrial fibrillation ablation outcome is predicted by left atrial remodeling on MRI. *Circ Arrhythm Electrophysiol*. 2014;7(1):23–30. <https://doi.org/10.1161/CIRCEP.113.000689>.
- 6.•• Marrouche NF, Wilber D, Hindricks G, Jais P, Akoum N, Marchlinski F, et al. Association of atrial tissue fibrosis identified by delayed enhancement MRI and atrial fibrillation catheter ablation: the DECAAF study. *JAMA*. 2014;311(5):498–506. <https://doi.org/10.1001/jama.2014.3> **This multicenter study aimed to evaluate the relationship of left atrial fibrosis degree based in UTAH score detected by LGE-MRI with clinical outcomes. They reported that for an increment of 1% of left atrial fibrosis, the possibilities of recurrent arrhythmia increase in a 6%.**
7. Corradi D. Atrial fibrillation from the pathologist's perspective. *Cardiovasc Pathol*. 2014;23(2):71–84. <https://doi.org/10.1016/j.carpath.2013.12.001>.
8. Nattel S, Burstein B, Dobrev D. Atrial remodeling and atrial fibrillation: mechanisms and implications. *Circ Arrhythm Electrophysiol*. 2008;1(1):62–73. <https://doi.org/10.1161/CIRCEP.107.754564>.
9. Kottkamp H. Human atrial fibrillation substrate: towards a specific fibrotic atrial cardiomyopathy. *Eur Heart J*. 2013;34(35):2731–8. <https://doi.org/10.1093/eurheartj/ehs194>.
10. Burstein B, Nattel S. Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation. *J Am Coll Cardiol*. 2008;51(8):802–9. <https://doi.org/10.1016/j.jacc.2007.09.064>.
11. Ambale-Venkatesh B, Lima JA. Cardiac MRI: a central prognostic tool in myocardial fibrosis. *Nat Rev Cardiol*. 2015;12(1):18–29. <https://doi.org/10.1038/nrcardio.2014.159>.
12. Bisbal F, Fernandez-Armenta J, Berruezo A, Mont L, Brugada J. Use of MRI to guide electrophysiology procedures. *Heart*. 2014;100(24):1975–84. <https://doi.org/10.1136/heartjnl-2013-304692>.
- 13.• Pontecorboli G, Figueras IVRM, Carlosena A, Benito E, Prat-Gonzales S, Padeletti L, et al. Use of delayed-enhancement magnetic resonance imaging for fibrosis detection in the atria: a review. *Europace*. 2017;19(2):180–9. <https://doi.org/10.1093/europace/euw053> **This article review summarizes and evaluate the current methodologies used to detect left atrial fibrosis by the different investigation groups.**
14. Akoum N, Daccarett M, McGann C, Segerson N, Vergara G, Kuppahally S, et al. Atrial fibrosis helps select the appropriate patient and strategy in catheter ablation of atrial fibrillation: a DE-MRI guided approach. *J Cardiovasc Electrophysiol*. 2011;22(1):16–22. <https://doi.org/10.1111/j.1540-8167.2010.01876.x>.
15. Chrispin J, Ipek EG, Habibi M, Yang E, Spragg D, Marine JE, et al. Clinical predictors of cardiac magnetic resonance late gadolinium enhancement in patients with atrial fibrillation. *Europace*. 2017;19(3):371–7. <https://doi.org/10.1093/europace/euw019>.
- 16.•• Khurram IM, Habibi M, Gucuk Ipek E, Chrispin J, Yang E, Fukumoto K, et al. Left atrial LGE and arrhythmia recurrence following pulmonary vein isolation for paroxysmal and persistent AF. *JACC Cardiovasc Imaging*. 2016;9(2):142–8. <https://doi.org/10.1016/j.jcmg.2015.10.015> **This study compared LGE extension in the left atrium before AF ablation with clinical outcomes after the procedures. The cut-off proposed by this group that better correlated with poor outcomes was >35% of LA fibrosis.**
- 17.•• Bisbal F, Guiu E, Cabanas-Grandio P, Berruezo A, Prat-Gonzalez S, Vidal B, et al. CMR-guided approach to localize and ablate gaps in repeat AF ablation procedure. *JACC Cardiovasc Imaging*. 2014;7(7):653–63. <https://doi.org/10.1016/j.jcmg.2014.01.014> **This was the first study to evaluate the feasibility of a guided MRI ablation approach in redo procedures targeting the anatomical gaps detected by LGE-MRI compared with**

- conventional approach. LGE-guided ablation led to reisolement of 95.6% of reconnected PVs.**
18. den Uijl DW, Cabanelas N, Benito EM, Figueras R, Alarcon F, Borrás R, et al. Impact of left atrial volume, sphericity, and fibrosis on the outcome of catheter ablation for atrial fibrillation. *J Cardiovasc Electrophysiol.* 2018;29(5):740–6. <https://doi.org/10.1111/jce.13482> **This single centre study evaluates the atrial remodelling markers characterized by MRI (fibrosis, sphericity, LA volume) in relationship with clinical outcomes after AF ablation. The strongest predictor of AF recurrences in this study was LA volume.**
 19. Linhart M, Alarcon F, Borrás R, Benito EM, Chipa F, Cozzari J, et al. Delayed gadolinium enhancement magnetic resonance imaging detected anatomic gap length in wide circumferential pulmonary vein ablation lesions is associated with recurrence of atrial fibrillation. *Circ Arrhythm Electrophysiol.* 2018;11(12):e006659. <https://doi.org/10.1161/CIRCEP.118.006659> **This study aims to characterize by LGE-MRI the induced RF lesions around the veins in order to localize the anatomical gaps for predicting outcomes after AF ablation. They report that the number of gaps was not correlated with recurrences but an increase of 10% relative gap length increased the likelihood of arrhythmia recurrence by 16%.**
 20. Harrison JL, Sohns C, Linton NW, Karim R, Williams SE, Rhode KS, et al. Repeat left atrial catheter ablation: cardiac magnetic resonance prediction of endocardial voltage and gaps in ablation lesion sets. *Circ Arrhythm Electrophysiol.* 2015. <https://doi.org/10.1161/CIRCEP.114.002066> **This study compares the site of electrical reconnection in re-ablation procedures with LGE signal intensity around the veins in a MRI performed before the procedure. The authors founded a weak inverse correlation, and no significant differences signal intensity between electrical reconnected and not reconnected regions.**
 21. Harrison JL, Jensen HK, Peel SA, Chiribiri A, Grondal AK, Bloch LO, et al. Cardiac magnetic resonance and electroanatomical mapping of acute and chronic atrial ablation injury: a histological validation study. *Eur Heart J.* 2014;35(22):1486–95. <https://doi.org/10.1093/eurheartj/ehs560> **This study aims to validate LGE signal intensities induced by the ablation lesions in pigs with an histopathological analysis of them. The SI thresholds that best approximated histological volumes were 2.3 SD above a reference for LGE post-ablation and 3.3 SD for LGE chronically.**
 22. Peters DC, Wylie JV, Hauser TH, Kissinger KV, Botnar RM, Essebag V, et al. Detection of pulmonary vein and left atrial scar after catheter ablation with three-dimensional navigator-gated delayed enhancement MR imaging: initial experience. *Radiology.* 2007;243(3):690–5. <https://doi.org/10.1148/radiol.2433060417>.
 23. Peters DC, Wylie JV, Hauser TH, Nezafat R, Han Y, Woo JJ, et al. Recurrence of atrial fibrillation correlates with the extent of post-procedural late gadolinium enhancement: a pilot study. *J Am Coll Cardiol Img.* 2009;2(3):308–16. <https://doi.org/10.1016/j.jcmg.2008.10.016>.
 24. Cochet H, Mouries A, Nivet H, Sacher F, Derval N, Denis A, et al. Age, atrial fibrillation, and structural heart disease are the main determinants of left atrial fibrosis detected by delayed-enhanced magnetic resonance imaging in a general cardiology population. *J Cardiovasc Electrophysiol.* 2015;26(5):484–92. <https://doi.org/10.1111/jce.12651>.
 25. Malcolm-Lawes LC, Juli C, Karim R, Bai W, Quest R, Lim PB, et al. Automated analysis of atrial late gadolinium enhancement imaging that correlates with endocardial voltage and clinical outcomes: a 2-center study. *Heart Rhythm.* 2013;10(8):1184–91. <https://doi.org/10.1016/j.hrthm.2013.04.030>.
 26. Sramko M, Peichl P, Wichterle D, Tintera J, Weichert J, Maxian R, et al. Clinical value of assessment of left atrial late gadolinium enhancement in patients undergoing ablation of atrial fibrillation. *Int J Cardiol.* 2015;179:351–7. <https://doi.org/10.1016/j.ijcard.2014.11.072>.
 27. Hwang SH, Oh YW, Lee DI, Shim J, Park SW, Kim YH. Evaluation of quantification methods for left atrial late gadolinium enhancement based on different references in patients with atrial fibrillation. *Int J Cardiovasc Imaging.* 2015;31(Suppl 1):91–101. <https://doi.org/10.1007/s10554-014-0563-0>.
 28. McGann C, Kholmovski E, Blauer J, Vijayakumar S, Haslam T, Cates J, et al. Dark regions of no-reflow on late gadolinium enhancement magnetic resonance imaging result in scar formation after atrial fibrillation ablation. *J Am Coll Cardiol.* 2011;58(2):177–85. <https://doi.org/10.1016/j.jacc.2011.04.008>.
 29. Hunter RJ, Jones DA, Boubertakh R, Malcolm-Lawes LC, Kanagaratnam P, Juli CF, et al. Diagnostic accuracy of cardiac magnetic resonance imaging in the detection and characterization of left atrial catheter ablation lesions: a multicenter experience. *J Cardiovasc Electrophysiol.* 2013;24(4):396–403. <https://doi.org/10.1111/jce.12063>.
 30. Chrispin J, Gucuk Ipek E, Zahid S, Prakosa A, Habibi M, Spragg D, et al. Lack of regional association between atrial late gadolinium enhancement on cardiac magnetic resonance and atrial fibrillation rotors. *Heart Rhythm.* 2016;13(3):654–60. <https://doi.org/10.1016/j.hrthm.2015.11.011>.
 31. Karim R, Housden RJ, Balasubramaniam M, Chen Z, Perry D, Uddin A, et al. Evaluation of current algorithms for segmentation of scar tissue from late gadolinium enhancement cardiovascular magnetic resonance of the left atrium: an open-access grand challenge. *J Cardiovasc Magn Reson.* 2013;15:105. <https://doi.org/10.1186/1532-429X-15-105>.
 32. Calkins H, Kuck KH, Cappato R, Brugada J, Camm AJ, Chen SA, et al. 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. *Europace.* 2012;14(4):528–606. <https://doi.org/10.1093/europace/eus027>.
 33. Verma A, Champagne J, Sapp J, Essebag V, Novak P, Skanes A, et al. Discerning the incidence of symptomatic and asymptomatic episodes of atrial fibrillation before and after catheter ablation (DISCERN AF): a prospective, multicenter study. *JAMA Intern Med.* 2013;173(2):149–56. <https://doi.org/10.1001/jamainternmed.2013.1561>.
 34. Verma A, Wazni OM, Marrouche NF, Martin DO, Kilicaslan F, Minor S, et al. Pre-existent left atrial scarring in patients undergoing pulmonary vein antrum isolation: an independent predictor of procedural failure. *J Am Coll Cardiol.* 2005;45(2):285–92. <https://doi.org/10.1016/j.jacc.2004.10.035>.
 35. Berruezo A, Tamborero D, Mont L, Benito B, Tolosana JM, Sitges M, et al. Pre-procedural predictors of atrial fibrillation recurrence after circumferential pulmonary vein ablation. *Eur Heart J.* 2007;28(7):836–41. <https://doi.org/10.1093/eurheartj/ehm027>.
 36. Bisbal F, Alarcon F, Ferrero-de-Loma-Osorio A, Gonzalez-Ferrer JJ, Alonso C, Pachon M, et al. Left atrial geometry and outcome of atrial fibrillation ablation: results from the multicentre LAGO-AF study. *Eur Heart J Cardiovasc Imaging.* 2018;19(9):1002–9. <https://doi.org/10.1093/ehjci/jeu060>.
 37. Bisbal F, Guiu E, Calvo N, Marin D, Berruezo A, Arbelo E, et al. Left atrial sphericity: a new method to assess atrial remodeling. Impact on the outcome of atrial fibrillation ablation. *J Cardiovasc Electrophysiol.* 2013;24(7):752–9. <https://doi.org/10.1111/jce.12116>.
 38. Akoum N, Morris A, Perry D, Cates J, Burgon N, Kholmovski E, et al. Substrate modification is a better predictor of catheter ablation success in atrial fibrillation than pulmonary vein isolation: an LGE-MRI study. *Clin Med Insights Cardiol.* 2015;9:25–31. <https://doi.org/10.1177/1077558715587155>.

- [org/10.4137/CMC.S22100](https://doi.org/10.4137/CMC.S22100) This study analyzed the impact of baseline fibrosis and the number of pulmonary veins completed encircled in LGE-MRI after AF ablation in outcomes. Baseline and residual fibrosis outside the veins were a better predictors of outcomes than completed enhancement around the veins.
39. Efficacy of delayed enhancement MRI-guided ablation vs conventional catheter ablation of atrial fibrillation (DECAAF II) [database on the Internet]. Available from: <https://www.clinicaltrials.gov/ct/show/NCT02529319>. Accessed: august 20, 2015. **This trial in an important multicenter randomized ongoing research about the clinical benefit of left atrial fibrosis areas isolation assessed by MRI in addition to PVI.**
 40. Isolation of pulmonary veins with the aid of magnetic resonance imaging (ALICIA) [database on the Internet]. Available from: <http://www.clinicaltrials.gov/ct2/show/NCT02698631>. Accessed 4 March 2016.
 41. Ouyang F, Antz M, Ernst S, Hachiya H, Mavrakis H, Deger FT, et al. Recovered pulmonary vein conduction as a dominant factor for recurrent atrial tachyarrhythmias after complete circular isolation of the pulmonary veins: lessons from double lasso technique. *Circulation*. 2005;111(2):127–35. <https://doi.org/10.1161/01.CIR.0000151289.73085.36>.
 42. Calkins H, Reynolds MR, Spector P, Sondhi M, Xu Y, Martin A, et al. Treatment of atrial fibrillation with antiarrhythmic drugs or radiofrequency ablation: two systematic literature reviews and meta-analyses. *Circ Arrhythm Electrophysiol*. 2009;2(4):349–61. <https://doi.org/10.1161/CIRCEP.108.824789>.
 43. Nademanee K, McKenzie J, Kosar E, Schwab M, Sunsaneewitayakul B, Vasavakul T, et al. A new approach for catheter ablation of atrial fibrillation: mapping of the electrophysiologic substrate. *J Am Coll Cardiol*. 2004;43(11):2044–53. <https://doi.org/10.1016/j.jacc.2003.12.054>.
 44. Verma A. The techniques for catheter ablation of paroxysmal and persistent atrial fibrillation: a systematic review. *Curr Opin Cardiol*. 2011;26(1):17–24. <https://doi.org/10.1097/HCO.0b013e3283413925>.
 45. Verma A, Jiang CY, Betts TR, Chen J, Deisenhofer I, Mantovan R, et al. Approaches to catheter ablation for persistent atrial fibrillation. *N Engl J Med*. 2015;372(19):1812–22. <https://doi.org/10.1056/NEJMoa1408288>.
 46. Boldt A, Wetzel U, Lauschke J, Weigl J, Gummert J, Hindricks G, et al. Fibrosis in left atrial tissue of patients with atrial fibrillation with and without underlying mitral valve disease. *Heart*. 2004;90(4):400–5.
 47. Kottkamp H, Berg J, Bender R, Rieger A, Schreiber D. Box isolation of fibrotic areas (BIFA): a patient-tailored substrate modification approach for ablation of atrial fibrillation. *J Cardiovasc Electrophysiol*. 2016;27(1):22–30. <https://doi.org/10.1111/jce.12870>.
 48. Rolf S, Kircher S, Arya A, Eitel C, Sommer P, Richter S, et al. Tailored atrial substrate modification based on low-voltage areas in catheter ablation of atrial fibrillation. *Circ Arrhythm Electrophysiol*. 2014;7(5):825–33. <https://doi.org/10.1161/CIRCEP.113.001251>.
 49. Yang G, Yang B, Wei Y, Zhang F, Ju W, Chen H, et al. Catheter ablation of nonparoxysmal atrial fibrillation using electrophysiologically guided substrate modification during sinus rhythm after pulmonary vein isolation. *Circ Arrhythm Electrophysiol*. 2016;9(2):e003382. <https://doi.org/10.1161/CIRCEP.115.003382>.
 50. Sanchez-Quintana D, Lopez-Minguez JR, Macias Y, Cabrera JA, Saremi F. Left atrial anatomy relevant to catheter ablation. *Cardiol Res Pract*. 2014;2014:289720–17. <https://doi.org/10.1155/2014/289720>.
 51. Benito EM, Andreu D, Mont L, Berruezo A. Correlation between functional electrical gaps identified by ultrahigh-density mapping and by late gadolinium enhancement cardiac magnetic resonance in repeat atrial fibrillation procedure. *HeartRhythm Case Rep*. 2017;3(5):282–5. <https://doi.org/10.1016/j.hrcr.2017.02.005>.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.